Imbria touts PhII success in hypertrophic cardiomyopathy, adding fuel to overall efficacy profile
07 Nov 2023
AHAPhase 2
Imbria Pharmaceuticals’ partial fatty acid oxidation inhibitorfatty acid oxidation inhibitor improved outcomes in Phase II non-obstructive hypertrophic cardiomyopathy patients, with the company noting that the asset’s efficacy could bode well for upcoming results in a separate heart failure trial.
Non-obstructive hypertrophic cardiomyopathy (nHCM) affects around one in 500 people, according to the American Heart Association, with a third of cases being non-obstructive. But heart failure with preserved ejection fraction (HFpEF) affects more people, with an estimated 2% of the population. Imbria’s ninerafaxstat is in Phase II development for both conditions.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.